ConductScience.org, home

Comparison · NCT03377790-d1f74b80

VP-102 vs Placebo: Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 42 Visit

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. VP-102 vs Placebo: Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 42 Visit. Trial comparisons, record NCT03377790-d1f74b80. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03377790-d1f74b80

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.2060.1510.275wilson
Risk in group 20.09430.05210.165wilson
Risk difference, group 1 minus group 20.1120.02210.193newcombe hybrid score
Risk ratio, group 1 over group 22.191.134.25log
Odds ratio, group 1 over group 22.491.175.31log
Number needed to treat, for one more participant with the outcome on VP-102 than on Placebo8.945.1845.3from the risk difference interval

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1VP-102
VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days~VP-102: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). VP-102 Active will be administered to Molluscum lesions
33160OG000
Group 2Placebo
Vehicle Film Forming Solution applied via a prefilled applicator to affected area every 21 days~Placebo: Placebo a single-use drug device combination product containing only the vehicle will be administered to Molluscum lesions
10106OG001

Outcome

Type
SECONDARY
Title
Percentage of Subjects Exhibiting Complete Clearance of All Treatable Molluscum Lesions (Baseline and New) on the Day 42 Visit
Description
Percentage of subjects exhibiting complete clearance of all treatable molluscum lesions (baseline and new) on the Day 42 visit.
Time frame
Day 1 (Baseline and new) compared to Day 42
Population
ITT Population

Source ClinicalTrials.gov

Trial

Title
Cantharidin Application in Molluscum Patients-1
NCT number
NCT03377790
Phases
PHASE3
Conditions
Molluscum Contagiosum
Interventions
VP-102 - Cantharidin, Topical Film Forming Solution, Placebo -Topical Film Forming Solution without VP-102
Lead sponsor
Verrica Pharmaceuticals Inc.
Results first posted
2021-12-14

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03377790-d1f74b80